ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0567

Determinants of Health-Related Quality of Life in Spondyloarthritis and Comparison with Chronic Low Back Pain – Results from a Nation-Wide Study
Abstract Number: 0568

Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
Abstract Number: 0569

All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis
Abstract Number: 0570

A Narrowed, but Persistent Mortality Gap: A National, Matched Cohort Study in U.S. Veterans with Rheumatoid Arthritis from 2000-2017
Abstract Number: 0571

The National Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2014-2016
Abstract Number: 0572

Circulating Cytokines and Chemokines Are Associated with the Risk of Incident Cardiovascular Disease in Rheumatoid Arthritis Independent of Conventional Disease Activity Measures
Abstract Number: 0573

Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
Abstract Number: 0574

Prevalence and Early Progression of Lung Diseases in Patients with Recently-Diagnosed Rheumatoid Arthritis: A Prospective Cohort Study
Abstract Number: 0575

World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015
Abstract Number: 0576

Associations of the MUC5B Promoter Variant with Timing of Articular Diagnosis and Interstitial Lung Disease in Rheumatoid Arthritis
Abstract Number: 0577

Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)
Abstract Number: 0578

Hyperinsulinemic Diet and Increased Risk of Female Gout: 2 Prospective Cohort Studies of US Women over 30 Years
Abstract Number: 0579

Predicting Treatment Change in Rheumatoid Arthritis Patients Treated with TNF Inhibitors as First-Line Biologic Agent
Abstract Number: 0580

Association Between Female Reproductive Factors and Gout: A Nationwide Population-based Cohort Study of 1 Million Postmenopausal Women
Abstract Number: 0581

Rheumatoid Arthritis Treatment Patterns in Massachusetts: Informative Findings from Insurance Claims Data

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].